46-store Irish retailer reports nearly €13 million more in annual online sales, with Rezolve Ai embedded in search and merchandising

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), the infrastructure platform powering agentic commerce, today said its customer Intersport Elverys, a nationwide Irish sports retailer, grew online revenue by 42% and lifted online conversion by 58% after deploying Rezolve Ai’s search and merchandising technology. The result comes as retailers enter the first agentic holiday season, with AI assistants sending shoppers to retailers’ sites ready to buy.

Founded in 1847, Intersport Elverys is wholly Irish owned, with 46 stores and more than 700 employees. It belongs to the INTERSPORT international retail network, which reported €14.1 billion in global omnichannel sales in 2025 across 5,260 stores in 40 countries. The results relate to Intersport Elverys’ online business.

Intersport Elverys previously managed online product placement by hand. Rezolve Ai automated merchandising across browsing and search, and the retailer reported these results, comparing its 2022 baseline with its most recent trading year:

  • Online conversion rose from 2.82% to 4.46%.
  • Annual online revenue rose from €31 million to €43.96 million, nearly €13 million more.
  • The team now spends more of its time on commercial strategy.

The project was a finalist for Digital Transformation Project of the Year at the 2026 RTIH Innovation Awards.

“Automating that process has freed us up to focus on the bigger picture, and the results speak for themselves,” said Clemon Wiggins, Team Lead/Online Merchandiser at Intersport Elverys.

Adobe expects AI-referred traffic to US retail sites to grow 130% year on year this holiday season and found that AI-referred visits in September converted 90% better than other traffic.

“The first agentic holiday season will reward the retailers that turn demand into revenue, and our customers are already doing it,” said Daniel M. Wagner, Founder, Chairman and CEO of Rezolve Ai. “The investment case for specialist AI starts with the customer’s economics. When we help a retailer convert more of the shoppers it already has, we earn a permanent place in how that business runs.”

“That is how durable relationships are built,” Wagner added. “We prove the value on one commercial task, then grow as customers bring more of their commerce onto our platform. I believe that is the strongest position anyone can hold in AI.”

Rezolve Ai Sits Inside the Daily Decisions That Drive Sales
Digital merchandising shapes which products shoppers see and how easily they find something to buy. Rezolve Ai places its technology inside those daily commercial decisions, and retailers can add RezolvePay, Rezolve Reward and Rezolve Insight through the same integration. Intersport Elverys plans to build on its existing deployment as further capabilities become available. Products are one of Rezolve Ai’s three growth engines, alongside partner-led distribution and infrastructure licensing.

Performance figures are customer-reported comparisons of overall online trading in the periods identified above.

Read the full customer case study at https://rezolve.com/customers/replacing-manual-merchandising-with-brain-commerce-for-intersport-to-drive-a-58-lift-in-conversion-rate/.

The November investor presentation is available on Rezolve Ai’s investor relations website at https://rezolve.com/reports/current-investor-presentation/.

About Rezolve Ai
Rezolve Ai is a global leader in AI-powered commerce and engagement. Its technology helps retailers, brands, financial institutions and commerce platforms create intelligent, personalized customer experiences across search, discovery, engagement and transaction journeys.

Rezolve Ai’s platform is designed to connect consumers, merchants, banks and payment providers through intelligent commerce infrastructure that makes customer interactions more relevant, measurable and valuable. Through its AI-powered commerce capabilities and Reward’s financial engagement platform, Rezolve Ai is building the infrastructure for the next generation of personalized and agentic commerce.

Media Contact
Urmee Khan
Group Director of Communications & Corporate Affairs
urmeekhan@rezolve.com
+44 7576 094 040

Forward-Looking Statements
This press release contains forward-looking statements, including statements about future platform adoption, customer relationships, expansion into additional capabilities, the development of agentic commerce, commercial opportunities and business growth.

These statements reflect management’s current expectations. Actual results may differ materially due to customer purchasing and renewal decisions, implementation performance, retail trading conditions, competition and other risks described in Rezolve Ai’s Annual Report on Form 20-F and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. Rezolve Ai undertakes no obligation to update them, except as required by law.

Results described for individual customers do not predict results for other deployments. Third-party data, forecasts and survey results have not been independently verified.

SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027.

The extension provides the FDA with additional time to review information provided in support of the NDA. Belite Bio remains committed to working closely with FDA throughout the review process, and is confident in the clinical evidence supporting tinlarebant and its potential to address the significant unmet medical need in the STGD1 patient population.

About Tinlarebant (a/k/a LBS-008)

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future expectations, plans and prospects, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding Belite Bio’s belief in the totality of evidence supporting tinlarebant and its ability to potentially bring tinlarebant as the first-ever approved treatment for STGD1, Belite Bio’s advancement of regulatory milestones and planned commercialization of its product candidates, FDA’s ongoing review of the NDA, the likelihood that the NDA will be approved and the timing of any approval decision, the tentative PDUFA date and anticipated date for the FDA to communicate proposed labeling requests and postmarketing requirement requests with the Company, as well as any other statements regarding matters that are not historical facts, and any other statements containing the words “may”, “will”, “expect”, “believe”, “target”, “plan”, “intend”, “continue”, “hope”, “potential”, “anticipate”, “estimate”, “remain”, “committed”, “confident”, “look forward”, and other similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors related to Belite Bio’s business, including but not limited to, Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; expectations for the timing of initiation, enrollment and completion of, and data relating to, its clinical trials; the timing to complete any ancillary clinical trials and/or to receive the interim/final data of such clinical trials; the timing to communicate with and submit trial data to regulatory authorities for drug approval in various jurisdictions; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio’s drug candidates; Belite Bio’s ability to successfully commercialize tinlarebant, if approved, including its ability to build out commercial infrastructure, achieve market acceptance, and execute a timely product launch; timing for Belite Bio to share additional data at upcoming medical meetings; the potential efficacy of tinlarebant to set a new benchmark for future research in inherited retinal disorders, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Media and Investor Relations Contact:
ir@belitebio.com  

NUC-7738 Increased Proteasome Inhibition When Combined with Carfilzomib

Data Presented Identify an Additional Potential Mode of Action for NUC-7738 and Support Evaluation of Additional Indications and Combination Strategies

BARCELONA, Spain, Nov. 20, 2026 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced new preclinical data showing that NUC-7738 enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor used to treat patients with multiple myeloma. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18–20, 2026.

Carfilzomib works by inhibiting the proteasome, a cellular system that breaks down unwanted proteins. Multiple myeloma cells depend heavily on this system to manage their high protein load. NuCana believes that increasing the effectiveness of proteasome inhibition could make these cancer cells more vulnerable to treatment.

In three multiple myeloma cell lines, NUC-7738 demonstrated single-agent activity and increased the anti-cancer activity of carfilzomib. At concentrations where the individual agents left approximately half of the cells viable, the combination reduced cell viability to 3% in two models and 26% in the third after 96 hours. In two of the three models, the combination’s activity exceeded that expected if the two agents acted independently; in the third, the effect was additive. These findings provide a scientific rationale for NuCana to further investigate the combination in multiple myeloma.

Further studies showed that NUC-7738 altered proteasome function and increased the inhibition achieved with carfilzomib. In one model, proteasome activity after 24 hours was 25% of the untreated control with the combination, compared with 52% with carfilzomib alone. NuCana believes this demonstrates a measurable effect on the cellular system targeted by carfilzomib and may help explain the combination’s greater anti-cancer activity.

NuCana believes the findings also suggest an additional potential mode of action for NUC-7738. Although NUC-7738 initially increased proteasome activity when used on its own, it also reduced the processed form of NFE2L1, a protein involved in the cellular response to proteasome inhibition. Our research proposes that NUC-7738’s active metabolite may influence the opening of the proteasome’s gate, potentially increasing access for carfilzomib. These observations offer a basis for investigating how NUC-7738 may increase cancer cells’ sensitivity to proteasome inhibitors. Further studies are needed to test this proposed mode of action and assess its relevance to treatment in patients.

NuCana believes these results also support further investigation beyond multiple myeloma. In a separate laboratory screen evaluating NUC-7738 with 70 partner drugs across 35 cancer cell lines, carfilzomib ranked first on a measure of greater-than-expected combination activity. Such activity was observed in 28 of 33 solid-tumor models spanning 14 tumor types, at a single concentration of NUC-7738. These findings highlight the broad anti-cancer potential of NUC-7738 and supports further evaluation to identify the cancer indications in which the combination may offer the greatest potential.

“These findings add an important dimension to our understanding of NUC-7738’s mode of action,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “What is particularly encouraging is that the changes in proteasome function were accompanied by greater-than-expected anti-cancer activity in these preclinical models. We believe these data strengthen the rationale for further evaluation of NUC-7738 in combination with proteasome inhibitors and across additional tumor types.”

Mr. Griffith continued: “Our priority is to define the optimal clinical development path for NUC-7738 in melanoma, informed by the forthcoming Phase 2 results and the latest translational data. We are also continuing our dialogue with the FDA regarding a potential registrational strategy. In parallel, we believe these new preclinical findings strengthen the scientific rationale for broadening the development of NUC-7738 beyond PD-1 inhibitor-resistant melanoma, through additional indications and combination strategies. With cash resources anticipated to fund our planned operations into 2029, we are focused on advancing these priorities and selecting the most promising opportunities for further development.”

As previously announced, NuCana plans to present final results from the Phase 2 expansion cohort of the NuTide:701 study, evaluating NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma, together with the latest translational data, at the ESMO Immuno-Oncology & Advanced Therapies Congress in London from December 14–16, 2026.

Details of NuCana’s presentation at the 38th EORTC-NCI-AACR Symposium are as follows:

Abstract Title: NUC-7738 Alters Functional Proteasome Activity and Enhances Carfilzomib Sensitivity in Multiple Myeloma
Poster Number: PB-084
Topic: Combination Therapies
Date: Friday, November 20, 2026
Presenting Author: Dr. Mustafa Elshani

More information regarding the 38th EORTC-NCI-AACR Symposium can be found at: https://event.eortc.org/ena2026/

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study that is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a targeted thymidylate synthase (“TS”) inhibitor designed to overcome key pharmacological limitations associated with other TS inhibitors. NUC-3373 has recently been evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer, and NuCana is currently evaluating further characterization of mode of action and target indications for further clinical studies of NUC-3373.

Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on March 19, 2026, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

NuCana plc
Hugh S. Griffith
Chief Executive Officer
+44 131-357-1111
info@nucana.com

ICR Healthcare
Chris Brinzey
+1 339-970-2843
chris.brinzey@icrhealthcare.com

Company’s 16-Qubit Algorithm Produces Results Advancing the Potential for More Computationally Efficient Nuclear Modeling

TEL AVIV, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) — Quantum X Labs (the “Company” or “QXL”), a developer of advanced quantum computing technologies, today announced a technological milestone achieved by its Nuclear Simulation Team, successfully executing a quantum algorithm designed to simulate photon transport through shielding materials on IBM’s Fez superconducting quantum processor.

The experiment demonstrated the ability of a 16-qubit quantum algorithm to accurately reproduce key characteristics of photon propagation, scattering, attenuation and detection through a two-dimensional tungsten collimator, producing results closely aligned with analytical calculations and classical simulations.

Beyond demonstrating accuracy, the significance of the experiment lies in the potential of quantum algorithms to reduce the computational resources required for complex nuclear simulations.

Conventional GPU-based Monte Carlo simulations rely on processing large numbers of individual particle histories to calculate radiation behavior, often requiring substantial computational resources. Quantum X Labs is developing an alternative approach that uses quantum-state preparation and reversible quantum operations to encode particle transport probabilities and evaluate detection outcomes.

In the experiment, each measurement point was evaluated using 4,096 quantum shots, with results closely matching classical references. The demonstrated circuit provides a foundation for future quantum amplitude estimation, which could reduce the sampling effort needed to estimate radiation transport probabilities. The experiment did not implement amplitude estimation or establish an efficiency advantage over GPU-based methods.

The experiment simulated the transport of 140 keV photons through a tungsten collimator, evaluating the effects of shielding attenuation, channel geometry and detector energy thresholds.

Following hardware-noise mitigation, the quantum algorithm demonstrated:

  • High accuracy: Root-mean-square deviations of approximately 0.03–0.04 compared with exact classical statevector simulation results.
  • Successful radiation modeling: Accurate reproduction of changes in photon detection probability resulting from variations in tungsten attenuation and channel width.
  • Real quantum hardware validation: Successful execution of the 16-qubit algorithm on IBM’s Fez superconducting quantum processor.

“What makes this achievement important is not simply that our quantum algorithm reproduced classical simulation results, but that we demonstrated a coherent and efficient oracle that can serve as a foundation for quantum amplitude estimation,” said David Shnaiderov, Head of Nuclear Quantum at Quantum X Labs. “Conventional GPU-based methods can require large numbers of particle histories. Our next objective is to integrate amplitude estimation and test whether it can deliver comparable accuracy with fewer sampling operations. Demonstrating the underlying circuit on real quantum hardware is an important step toward that goal.”

Radiation transport simulation plays an important role across the nuclear energy, aerospace, defense, medical imaging and radiation shielding industries. More computationally efficient simulation methods could support increasingly complex system designs while potentially reducing computational requirements.

Quantum X Labs intends to expand the complexity of its nuclear simulation algorithms, integrate quantum amplitude estimation with the demonstrated oracle, and benchmark sampling requirements and computational performance against GPU-accelerated Monte Carlo methods.

Quantum X Labs Inc.

 Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses its plans to further develop and expand the complexity of its nuclear simulation algorithms; its plans to integrate quantum amplitude estimation with its demonstrated quantum algorithm and benchmark sampling requirements and computational performance against GPU-accelerated Monte Carlo methods; the potential of quantum algorithms and quantum amplitude estimation to reduce the sampling effort and computational resources required for radiation transport simulations; and the potential applications of such technologies.; expectations regarding the size, growth and development of the quantum cybersecurity market and related market opportunities; the Company’s ability to identify, pursue and benefit from such opportunities; expected demand for quantum-security technologies; and the Company’s plans, objectives, expectations and beliefs regarding future developments in quantum cybersecurity. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites.

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com 

To Nasdaq Copenhagen and the Press

Refinancing of floating rate loans

The Nykredit Group has completed the auctions in connection with the refinancing of floating rate loans on 1 January 2027.

The results of the auctions are shown below. The spreads will be in force until the next refinancing.

  Cita-loan
ISIN DK000955566-6
Reference rate Cita6M
Cover pool H (SDO)
Series 32H
Callable No
Auction results  
Total allotment DKK 13,900 mio.
Total bids DKK 45,144 mio.
Interest rate spread +0.56%
Price 100.20
Other information  
Maturity 01-07-2030

Enquiries may be addressed to Group Treasury, Emil Schmidt Andreasen, tel. +45 44 55 22 72.

Attachment

To Nasdaq Copenhagen and the press

Refinancing of floating rate loans

The Nykredit Group has completed the auctions in connection with the refinancing of floating rate loans on 1 January 2027.

The results of the auctions are shown below. The spreads will be in force until the next refinancing.

  Cita-loan
ISIN DK000955566-6
Reference rate Cita6M
Cover pool H (SDO)
Series 32H
Callable No
Auction results  
Total allotment DKK 13,900 mio.
Total bids DKK 45,144 mio.
Interest rate spread +0.56%
Price 100.20
Other information  
Maturity 01-07-2030

Enquiries may be addressed to Group Treasury, Emil Schmidt Andreasen, tel. +45 44 55 22 72.

Attachment

Management report

Pro Kapital delivered a resilient performance during the first nine months of 2026, remaining profitable, maintaining a stable gross profit margin of 35% and strengthening its financial position. The Group continued to advance its residential developments across all three Baltic capitals, supported by its diversified portfolio and disciplined approach to project execution.

The year began with improving sentiment in the Baltic real estate market, although geopolitical uncertainty and inflationary pressures subsequently affected buyer confidence. In Tallinn, residential projects in Kristiine City performed broadly in line with expectations, while the Group’s premium developments in Vilnius achieved strong market positioning. In Riga, construction progressed at Blue Marine Residence.

A major highlight of the reporting period was the highly successful public bond offering in September 2026, demonstrating strong investor confidence in Pro Kapital. The offering was twice oversubscribed, attracting 985 investors across all three Baltic countries and subscriptions totalling EUR 12.0 million. In response to the strong demand, the Group increased the issue size to the maximum of EUR 10 million. The new unsecured bonds carry a fixed annual interest rate of 8.3%, payable quarterly, and mature on 25 September 2028.

The proceeds were used for the full early redemption of the Group’s senior secured bonds in October 2026. Together with the extension of its existing unsecured bonds, this means that all outstanding bonds now mature in the second half of 2028, providing greater predictability in the Group’s financing structure.

These achievements reinforce our confidence in the direction we have chosen. We will continue to focus on delivering high-quality developments, completing ongoing projects and carefully timing new investments according to demand in each market. Our priority is not growth for its own sake, but delivering on our commitments to customers and investors.

Key financials

The Group remained profitable in the first nine months of 2026, with revenue of EUR 31.7 million (9M 2025: EUR 34.3 million) and net profit of EUR 2.0 million (9M 2025: EUR 6.0 million). Gross margin held steady at 35%.

The lower result was partly attributable to a decrease in real estate sales volumes (from 5 000 m² in the first nine months of 2025 to 4 484 m² in the corresponding period of 2026), higher marketing and administrative expenses and a one-off revaluation gain that supported the comparative period. Net profit was further affected by income tax on the Group’s profitable development in Lithuania.

Third-quarter revenue was broadly unchanged at EUR 5.6 million (Q3 2025: EUR 5.7 million). However, slightly lower sales volumes and a shift in the sales mix towards lower-margin projects reduced the gross margin to 25% (Q3 2025: 30%). The quarter closed with an operating loss of EUR 0.8 million (Q3 2025: operating profit of EUR 0.2 million) and a net loss of EUR 1.3 million (Q3 2025: net loss of EUR 0.2 million).

Cash generated from operating activities in the first nine months amounted to EUR 5.4 million (9M 2025: EUR 6.8 million), while EUR 3.9 million was used in the third quarter of 2026, reflecting ongoing construction investment.

Net asset value per share increased by 15% year-on-year, reaching EUR 1.15 as at 30 September 2026, compared to EUR 1.00 a year earlier, reflecting the continued strengthening of the Group’s equity position.

Key performance indicators

in thousands of euros 2026 9M 2025 9M 2026 Q3 2025 Q3 2025 12M
Revenue 31 684 34 265 5 597 5 746 53 162
Gross profit 10 941 11 934 1 380 1 701 18 795
Gross profit, % 35% 35% 25% 30% 35%
Operating profit 4 746 7 668 -807 151 14 733
Operating profit, % 15% 22% -14% 3% 28%
Net profit (incl. non-controlling interests) 2 048 6 025 -1 253 -163 12 041
Net profit (incl. non-controlling interests), % 6% 18% -22% -3% 23%
Net profit (owners’ share) 2 223 6 292 -1 202 -50 12 314
Earnings per share (owners’ share), EUR 0.04 0.11 -0.02 0.00 0.22

 in thousands of euros 30.09.2026 30.09.2025 31.12.2025
Total Assets 132 799 120 694 124 490
Total Liabilities 67 424 63 728 61 163
Equity (incl. non-controlling interests) 65 375 56 966 63 327
Equity (owners’ share) 65 369 56 779 63 146
       
Equity ratio, % 49.2% 47.0% 50.7%
Return on equity, % 3.6% 11.7% 21.6%
Return on assets, % 1.8% 5.1% 9.9%
LTV*, % 53.6% 45.6% 45.3%
Net debt to equity 0.57 0.73 0.63
Current ratio 3.62 4.08 1.56
Net asset value per share, EUR 1.15 1.00 1.11

*LTV as at 30 September 2026 is temporarily elevated due to the timing of the bond refinancing. As at that date, the balance sheet includes both the new unsecured bonds (ISIN EE0000005130) in the amount of EUR 10 million, issued on 25 September 2026, and the senior secured bonds 2020/2028 (ISIN SE0013801172) in the amount of EUR 10.5 million, which were refinanced by the new issue and redeemed in full on 19 October 2026, i.e. after the reporting date.

Equity ratio = equity (owners’ share)/ total assets
Return on equity = net profit (owners’ share) / average equity (owners’ share)
Return on assets = net profit (owners’ share) / average total assets
LTV = total debt / value of real estate assets (inventories and investment property)
Net debt to equity ratio = current and non-current debt less cash/ equity (owners’ share)
Current ratio = current assets / current liabilities
Net asset value per share = equity (owners’ share) / number of shares

Real Estate Development

Tallinn

Pro Kapital continued to make strong progress across its Tallinn residential developments during the first nine months of 2026. Sales in Kristiine City remained broadly in line with expectations, supported by demand for well-located, high-quality homes, while construction advanced across several projects. With completed developments generating ongoing sales and a substantial pipeline of new residential properties, the Group remains well positioned for continued development in the Estonian capital.

In Kristiine City, the Uus-Kindrali development made solid progress in both sales and construction. As at the date of publication of this report, 93.5% of the total apartments in the white building (Talli 3 / Sammu 8) had been sold, with 6 apartments still available for sale.

Meanwhile, construction of the adjacent seven-storey black building at Sammu 10/Seebi 24a, comprising 90 apartments, was nearing completion. During September, final inspections were carried out with the subcontractors to be ready for client inspections in October. As of the publication date of this report, client inspections are in full swing, the first real rights agreements have been signed and units have been delivered to clients. By the date of publication, 55.6% of the total apartments had been sold.

Sales and construction also continued at Musketäri Majad, a development launched in the first quarter of 2026. Located at Sammu 7, Talli 1 and Rivi 8, the project comprises two six- and seven-storey buildings with a total of 144 apartments. By the end of the third quarter, Sammu 7 had reached its full height and Talli 1 had 4 of its 7 floors completed. At Rivi 8, most of the underground concrete works have been completed.

Looking ahead, the Group continues preparations for its Dunte development at Tondi Street 53, for which a building permit has already been obtained. The start of construction will be determined in line with market conditions and the Group’s development strategy.

The remaining projects in the Kristiine City development portfolio are in the active design stage. The building permits for NÜÜD Houses (Marsi 1 / Sõjakooli 13 and Sammu 2/4 / Sõjakooli 15) have been issued, subject to certain conditions agreed with the city, including the developer’s obligation to construct and transfer public infrastructure, such as pedestrian sidewalks, to the municipality. In total, these developments are expected to add approximately 43 000 square metres of above- and below-ground gross building area and around 360 units. Approximately 95% of these units would be residential and 5% commercial. This pipeline provides significant opportunities for future growth while allowing the Group to align new investments with market demand.

In the Kalaranna District, construction has been completed and sales continue. As at the publication date, 89% of the development’s 385 apartments had been sold, with 43 remaining available. The project reinforces Pro Kapital’s position in Tallinn’s premium residential segment, offering distinctive architecture and a prime waterfront location.

Riga

In Riga, Pro Kapital continued to make progress with its Blue Marine Residence development in Klīversala Bay, with construction advancing above ground level during the third quarter. Sales and marketing activities continued alongside the development of the broader Klīversala Bay brand, supporting the project’s market positioning and the Group’s long-term ambitions in Riga.

Vilnius

In Vilnius, the Group maintained sales momentum at the Attico and City Villas developments and continued notary sales.

In September, the Group officially completed and unveiled City Villas, its premium residential development in Vilnius Old Town, representing an investment of more than EUR 21 million. Located at the intersection of Šaltinių and Aguonų streets, the completed development comprises four four-storey residential villas and the Attico Boutique commercial building. City Villas marks the architectural highlight of an area developed by Pro Kapital over more than a decade, distinguished by its unique architecture, spacious residences and elevated position overlooking the historic rooftops of Vilnius Old Town.

The Group also advanced its newest premium development, Borgo, located in Vilnius Old Town adjacent to the MO Museum. Construction works commenced during the third quarter, marking an important milestone in the project’s development.

Hotel operations

Third-quarter performance was broadly in line with last year, despite softer demand in July compared with both the previous year and the budget. This was offset by a record-breaking September, with average occupancy reaching 90%, the highest ever recorded by the hotel.
The outlook for the fourth quarter remains positive in the individual segment, which is ahead of the same period last year, although MICE demand remains softer.

Year-to-date profitability is above last year but still below budget, which nevertheless remains within reach.

Conclusion

Looking ahead, our priority is to complete ongoing developments, deliver homes to buyers and maintain sales momentum across our Baltic markets. At the same time, we have a substantial pipeline of future projects, giving us the flexibility to decide when to launch new developments based on demand in each market.

We believe that success in the current market depends not on how quickly a developer expands, but on how consistently it delivers. For Pro Kapital, this means keeping our commitments to customers, maintaining high standards and making investment decisions that support the company’s long-term financial strength.

CONSOLIDATED INTERIM FINANCIAL STATEMENTS 
Consolidated interim statements of financial position

in thousands of euros 30.09.2026 30.09.2025 31.12.2025
ASSETS      
Current assets      
  Cash 16 995 4 925 5 143
  Current receivables 611 962 5 645
  Prepayments 792 667 287
  Inventories 66 670 60 879 57 503
Total current assets 85 068 67 433 68 578
Non-current assets      
  Non-current receivables 12 313 324
  Property, plant and equipment 9 047 7 394 7 836
  Right-of-use-assets 726 320 781
  Investment property 35 361 42 532 43 516
  Goodwill 0 863 0
  Intangible assets 685 1 839 1 555
Total non-current assets 45 831 53 261 54 012
  Assets held for sale 1 900 0 1 900
Total assets held for sale 1 900 0 1 900
TOTAL ASSETS 132 799 120 694 124 490
LIABILITIES AND EQUITY      
Current liabilities      
  Current debt 11 811 1 230 30 046
  Customer advances 3 624 8 670 5 888
  Trade and other payables 6 545 6 637 7 534
  Income tax liabilities 1 387 1 475
  Short-term provisions 156 5 116
Total current liabilities 23 523 16 543 44 059
Non-current liabilities      
  Non-current debt 42 243 45 272 15 053
  Other non-current payables 8 6 8
  Deferred income tax liabilities 1 355 1 788 1 813
  Long-term provisions 295 119 230
Total non-current liabilities 43 901 47 185 17 104
TOTAL LIABILITIES 67 424 63 728 61 163
Equity attributable to equity holders of the parent      
  Share capital in nominal value 11 338 11 338 11 338
  Share premium 5 661 5 661 5 661
  Statutory reserve 1 134 1 134 1 134
  Revaluation surplus 2 322 1 977 2 322
  Retained earnings 44 914 36 669 42 691
Total equity attributable to equity holders of the parent 65 369 56 779 63 146
Non-controlling interest 6 187 181
TOTAL EQUITY 65 375 56 966 63 327
TOTAL LIABILITIES AND EQUITY 132 799 120 694 124 490

Consolidated interim statements of comprehensive income
 
in thousands of euros 2026 9M 2025 9M 2026 Q3 2025 Q3 2025 12M  
CONTINUING OPERATIONS            
Revenue 31 684 34 265 5 597 5 746 53 162  
Cost of sales -20 743 -22 331 -4 217 -4 045 -34 367  
Gross profit 10 941 11 934 1 380 1 701 18 795  
             
Marketing expenses -1 271 -933 -620 -307 -1 213  
Administrative expenses -4 965 -4 225 -1 585 -1 473 -5 659  
Other operating income 109 1 015 33 245 3 824  
Other operating expenses -68 -123 -15 -15 -1 014  
Operating profit/ -loss 4 746 7 668 -807 151 14 733  
             
Finance income 25 30 8 7 40  
Finance cost -1 787 -1 914 -486 -400 -2 615  
Profit/ -loss before income tax 2 984 5 784 -1 285 -242 12 158  
Income tax -936 241 32 79 -117  
Profit/ -loss for the period 2 048 6 025 -1 253 -163 12 041  
Attributable to:            
Equity holders of the parent 2 223 6 292 -1 202 -50 12 314  
Non-controlling interest -175 -267 -51 -113 -273  
             
Other comprehensive income            
Items that will not be reclassified subsequently to profit or loss        
Net change in asset revaluation reserve 0 0 0 0 345  
Other comprehensive income for the period 0 0 0 0 345  
Total comprehensive income for the period 2 048 6 025 -1 253 -163 12 386  
Attributable to:            
Equity holders of the parent 2 223 6 292 -1 202 -50 12 659  
Non-controlling interest -175 -267 -51 -113 -273  
             
Earnings per share (Basic) EUR 0.04 0.11 -0.02 0.00 0.22  

The full report can be found in the file attached.

Edoardo Axel Preatoni
CEO
+372 614 4920
prokapital@prokapital.com

Attachment

HOUSTON, Nov. 20, 2026 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced financial results for the quarter and fiscal year ended September 30, 2026.

Fourth Quarter 2026 Highlights

  • Revenue of $1.39 billion for the fourth quarter of fiscal 2026, an increase of 55% compared with $898 million for the same quarter of fiscal 2025
  • Operating income of $217.2 million for the fourth quarter of fiscal 2026, an increase of 108% compared with $104.3 million for the same quarter of fiscal 2025
  • Net income attributable to IES of $182.3 million for the fourth quarter of fiscal 2026, an increase of 79% compared with $101.8 million for the same quarter of fiscal 2025, and diluted earnings per share attributable to common stockholders of $4.50 for the fourth quarter of fiscal 2026, compared with $2.49 for the same quarter of fiscal 2025
  • Adjusted net income attributable to IES (a non-GAAP financial measure, as defined below) of $165.1 million for the fourth quarter of fiscal 2026, an increase of 114% compared with $77.0 million for the same quarter of fiscal 2025, and diluted adjusted earnings per share attributable to common stockholders of $4.07 for the fourth quarter of fiscal 2026, compared with $1.88 for the same quarter of fiscal 2025
  • Remaining performance obligations, a GAAP measure of future revenue to be recognized from current contracts with customers, of approximately $3.48 billion as of September 30, 2026
  • Backlog (a non-GAAP financial measure, as defined below) of approximately $4.96 billion as of September 30, 2026
  • Subsequent to quarter end, on October 5, 2026, completed the acquisition of DBM Global, adding a new Structural line of business and expanded our credit facility from $300 million to $700 million
  • Subsequent to quarter end, our Board of Directors authorized an additional $350 million for our share repurchase program

Fiscal Year 2026 Highlights

  • Revenue of $4.48 billion for fiscal 2026, an increase of 33% compared with $3.37 billion for fiscal 2025
  • Operating income of $605.7 million for fiscal 2026, an increase of 58% compared with $383.5 million for fiscal 2025
  • Net income attributable to IES of $536.6 million for fiscal 2026, an increase of 75% compared with $306.0 million for fiscal 2025, and diluted earnings per share attributable to common stockholders of $13.24 for fiscal 2026, compared with $7.51 for fiscal 2025
  • Adjusted net income attributable to IES of $459.8 million for fiscal 2026, an increase of 66% compared with $277.8 million for fiscal 2025, and diluted adjusted earnings per share attributable to common stockholders of $11.34 for fiscal 2026 compared with $6.81 for fiscal 2025

Overview of Results

“We are pleased to report outstanding operating performance, resulting in record earnings for fiscal year 2026,” said Matt Simmes, President and Chief Executive Officer. “Year-over-year consolidated revenue increased 33% and operating income increased 58%, driven by strong execution by our operating teams, our continued investment in growth, and the strength of the key markets in which we operate. I also want to recognize our teams for their focus on continuous improvement in safety over the year, reinforcing our commitment to a strong safety culture across the organization. With record levels of backlog at September 30, 2026, we expect continued strong organic growth in fiscal 2027 in our Communications, Commercial & Industrial and Infrastructure Solutions segments.” 

“In October 2026 we completed our acquisition of DBM Global, establishing a new Structural line of business. We are excited about the addition of DBM Global’s engineering, fabrication and erection capabilities and approximately 4,000 skilled employees to the IES team. The addition of DBM Global broadens the range of products and services we offer our customers, and we are optimistic about the new business opportunities that its skilled workforce and over two million square feet of operating facilities will enable in fiscal 2027. This acquisition also added backlog of $2.6 billion, which is not included in our September 30, 2026 backlog amounts described above.”

Our Communications segment’s revenue was $1.69 billion in fiscal 2026, an increase of 48% compared with fiscal 2025, driven by investments we have made in the business to keep pace with the continuously increasing demand from our customers in the data center end market. The segment’s operating income increased to $290.0 million for fiscal 2026, compared with $166.5 million for fiscal 2025, as we benefited from strong project execution, our ability to scale effectively, and strong market conditions.

Our Commercial & Industrial segment’s revenue was $799.5 million in fiscal 2026, an increase of 83% compared with fiscal 2025. The increase in revenue was primarily driven by continued strong demand and successful execution in the data center end market, as we benefited from our efforts to expand our capabilities and trained workforce in that space. Segment operating income for fiscal 2026 was $163.1 million, compared with $47.3 million for fiscal 2025. Our operating margins, particularly in the second half of fiscal 2026, benefited from some large, quick-turning projects we executed at favorable margins, and our teams rose to the challenge of executing these projects successfully.

Our Infrastructure Solutions segment’s revenue was $826.6 million in fiscal 2026, an increase of 66% compared with fiscal 2025, driven by continued strong demand in our custom engineered solutions business, primarily for the data center end market, where investments we have made in capacity over the past several years have enabled us to meet customer demand. Operating income for fiscal 2026 was $194.4 million, compared with $118.5 million for fiscal 2025. The year-over-year profit improvement was driven by higher volumes and improved pricing. Operating income as a percent of revenue decreased year over year, as we continue to invest in our more recent acquisitions, which typically come on line at a lower margin than more mature facilities. However, this impact was largely mitigated by our ability to efficiently scale fixed costs as we grow. Gulf Island, which we acquired in January 2026, contributed $151 million of revenue and $11 million of operating income for the fiscal year.

Our Residential segment’s revenue was $1.22 billion in fiscal 2026, a decrease of 7% compared with fiscal 2025, reflecting weak demand in the housing market, which continues to be affected by housing affordability challenges, elevated mortgage rates, availability and cost of insurance, and overall economic uncertainty. However, the impact of these factors was partly offset by continued expansion of our plumbing and HVAC trades into new geographic markets. As the cost of inputs rose throughout fiscal 2026, weak demand limited our ability to recover cost increases through pricing actions in our single-family business. In our multi-family business, lower revenue year-over-year reflects the impacts of prolonged elevated borrowing costs for project owners, which resulted in lower backlog entering fiscal 2026. As a result of these factors, the Residential segment’s operating income was $40.1 million for fiscal 2026, compared with $103.8 million for fiscal 2025.

“As we look forward to fiscal 2027, we are optimistic about our outlook for continued strong performance based on our existing and recently added operating capabilities and capacity, in combination with the favorable environment in many of the industries we serve, and we intend to continue aggressive pursuit of organic growth and selective acquisitions,” said Jeff Gendell, Executive Chairman. “We structured our financing of the DBM Global acquisition intentionally, balancing the use of cash, equity and borrowings under our credit facility to provide flexibility for future opportunities to grow our business. Subsequent to our fiscal 2026 year end, we took advantage of the stock market disruptions impacting trading prices in our industry to repurchase 350,000 shares of our common stock at an average price of $248.00, substantially mitigating the dilutive impact of the shares issued as part of the consideration for the purchase of DBM Global. On November 19, our Board of Directors authorized an additional $350 million for our share repurchase program.”

Capital Allocation; Stock Buyback Plan

“We ended the year with $155.1 million of cash, $288.9 million of marketable securities and no debt, positioning us advantageously to complete our acquisition of DBM Global after the close of the fiscal year,” added Tracy McLauchlin, Chief Financial Officer. “On October 5, 2026, in connection with that transaction, we expanded our credit facility from $300 million to $700 million, and borrowed $525 million to fund the acquisition. Through November 19, 2026, we have repaid $125 million of that borrowing. We expect strong operating cash flow generation from the business in fiscal 2027, which we will use to repay debt and fund capital expenditures to support continued growth, maintaining flexibility for other capital allocation priorities.”

Capital allocation highlights during fiscal 2026 include the following:

  • We invested $143.1 million to acquire Gulf Island
  • We supported the growth of our operating businesses with $163.1 million in capital expenditures
  • We repurchased 26,465 shares of our common stock for $7.2 million, or an average price of $270.59 per share, ending the year with $160.8 million remaining under our stock repurchase authorization
  • We used $245.3 million of our excess cash to purchase marketable securities

Capital allocation highlights subsequent to the end of the fiscal year include:

  • On October 5, 2026, we expanded our credit facility from $300 million to $700 million and borrowed $525 million to fund our acquisition of DBM Global
  • Through November 19, 2026, we repurchased an additional 350,000 shares of our common stock for $86.8 million, or an average price of $248.00 per share
  • On November 19, 2026, our Board of Directors approved an additional $350 million for our stock repurchase program

Non-GAAP Financial Measures and Other Adjustments

This press release includes adjusted net income attributable to IES, adjusted diluted earnings per share attributable to common stockholders, and backlog, and, in the non-GAAP reconciliation tables included herein, adjusted net income attributable to common stockholders, EBITDA, adjusted EBITDA and adjusted income from operations before income taxes, each of which is a financial measure not calculated in accordance with generally accepted accounting principles in the U.S. (“GAAP”). Management believes that these measures provide useful information to our investors by, in the case of adjusted net income attributable to IES, adjusted net income attributable to common stockholders, adjusted earnings per share attributable to common stockholders, adjusted EBITDA and adjusted income from operations before income taxes, distinguishing certain nonrecurring events such as litigation settlements, significant expenses associated with leadership changes, or gains or losses from the sale of a business, noncash events, such as impairment charges, items that are not indicative of quarterly business performance such as gains and losses on our investments, or, in the case of backlog, providing a common measurement used in IES’s industry, as described further below, and that these measures, when reconciled to the most directly comparable GAAP measures, help our investors to better identify underlying trends in the operations of our business and facilitate easier comparisons of our financial performance with prior and future periods and to our peers. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures, which has been provided in the financial tables included in this press release.

Remaining performance obligations represent the unrecognized revenue value of our contract commitments. While backlog is not a defined term under GAAP, it is a common measurement used in IES’s industry and IES believes this non-GAAP measure enables it to more effectively forecast its future results and better identify future operating trends that may not otherwise be apparent. IES’s remaining performance obligations are a component of IES’s backlog calculation, which also includes signed agreements and letters of intent which we do not have a legal right to enforce prior to work starting. These arrangements are excluded from remaining performance obligations until work begins. IES’s methodology for determining backlog may not be comparable to the methodologies used by other companies.

For further details on the Company’s financial results, please refer to the Company’s annual report on Form 10-K for the fiscal year ended September 30, 2026, to be filed with the Securities and Exchange Commission (“SEC”) by November 20, 2026, and any amendments thereto.

About IES Holdings, Inc.

IES designs and installs integrated electrical and technology systems, provides infrastructure solutions and services, and delivers structural steel engineering, fabrication and erection to a variety of end markets, including data centers, residential housing, and commercial, industrial and infrastructure facilities. Our more than 16,000 employees serve clients primarily in the United States. For more information about IES, please visit www.ies-co.com.

Company Contact:

Tracy McLauchlin
Chief Financial Officer
IES Holdings, Inc.
(713) 860-1500
investor.relations@ies-co.com

Investor Relations Contact:

Robert Winters
Alpha IR Group
312-445-2870
IESC@alpha-ir.com

Certain statements in this release may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, all of which are based upon various estimates and assumptions that the Company believes to be reasonable as of the date hereof. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “seek,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology. These statements involve risks and uncertainties that could cause the Company’s actual future outcomes to differ materially from those set forth in such statements. Such risks and uncertainties include, but are not limited to, a general reduction in the demand for our products or services; changes in general economic conditions, including supply chain constraints, high rates of inflation, changes in consumer sentiment, elevated interest rates, and market disruptions resulting from a number of factors, including geo-political events; competition in the industries in which we operate, which could result in the loss of one or more customers or lead to lower margins on new projects; the use of estimates in placing bids on fixed price contracts, variations from estimated contract costs and our ability to successfully manage and execute projects, the cost and availability of qualified labor and the ability to maintain positive labor relations, and our ability to pass along increases in the cost of commodities used in our business; our ability to enter into, and the terms of, future contracts; the existence of a small number of customers from whom we derive a meaningful portion of our revenues; reliance on third parties, including subcontractors and suppliers, to complete our projects; the inability to carry out plans and strategies as expected, including the inability to identify and complete acquisitions that meet our investment criteria, or the subsequent underperformance of those acquisitions; challenges integrating new businesses into the Company or new types of work, products or processes into our segments; backlog that may not be realized or may not result in profits; failure to adequately recover on contract change orders or claims against customers; closures or sales of our facilities resulting in significant future charges or a significant disruption of our operations; the impact of future epidemics or pandemics on our business; an increased cost of surety bonds affecting margins on work and the potential for our surety providers to refuse bonding or require additional collateral at their discretion; the impact of seasonality, adverse weather conditions, and climate change; fluctuations in operating activity due to factors such as cyclicality, downturns in levels of construction or the housing market, and differing regional economic conditions; difficulties in managing our billings and collections; accidents resulting from the physical hazards associated with our work and the potential for accidents; the possibility that our current insurance coverage may not be adequate or that we may not be able to obtain policies at acceptable rates; the effect of litigation, claims and contingencies, including warranty losses, damages or other latent defect claims in excess of our existing reserves and accruals; costs and liabilities under existing or potential future laws and regulations, including those laws and regulations related to the environment and climate change, as well as the inability to transfer, renew and obtain electrical and other professional licenses; interruptions to our information systems and cyber security or data breaches; expenditures to conduct environmental remediation activities required by certain environmental laws and regulations; loss of key personnel, ineffective transition of new management, or general labor constraints; credit and capital market conditions, including changes in interest rates that affect the cost of construction financing and mortgages, and the inability of some of our customers to obtain sufficient financing at acceptable rates, which could lead to project delays or cancellations; limitations on our ability to access capital markets and generate cash from operations to fund our capital needs; the impact on our effective tax rate or cash paid for taxes from changes in tax positions we have taken or changes in tax laws; difficulty in fulfilling the covenant terms of our credit facility, which could result in a default and acceleration of any indebtedness under such credit facility; reliance on certain estimates and assumptions that may differ from actual results in the preparation of our financial statements and the impacts of new accounting, control and operating procedures resulting from new accounting pronouncements; uncertainties inherent in the use of percentage-of-completion accounting, which could result in the reduction or elimination of previously recorded revenues and profits; the recognition of potential goodwill, long-lived assets and other investment impairments; the existence of a controlling shareholder, who has the ability to take action not aligned with other shareholders or to dispose of all or a significant portion of the shares of our common stock it holds, which may trigger certain change of control provisions in a number of our material agreements; the relatively low trading volume of our common stock, which could increase the volatility of our stock price and could make it more difficult for shareholders to sell a substantial number of shares for the same price at which shareholders could sell a smaller number of shares; the possibility that we issue additional shares of common stock, preferred stock or convertible securities that will dilute the percentage ownership interest of existing stockholders and may dilute the value per share of our common stock; the potential for substantial sales of our common stock, which could adversely affect our stock price; the impact of increasing scrutiny and changing expectations from investors and customers, or new or changing regulations, with respect to climate change or environmental impacts of our operations; the cost or effort required for our shareholders to bring certain claims or actions against us, as a result of our designation of the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings; and the possibility that our internal controls over financial reporting and our disclosure controls and procedures may not prevent all possible errors that could occur, as well as other risk factors discussed in this document, in the Company’s annual report on Form 10-K for the year ended September 30, 2026 and in the Company’s other reports on file with the SEC. You should understand that such risk factors could cause future outcomes to differ materially from those experienced previously or those expressed in such forward-looking statements. The Company undertakes no obligation to publicly update or revise any information or any forward-looking statements to reflect events or circumstances that may arise after the date of this release.

Forward-looking statements are provided in this press release pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of the estimates, assumptions, uncertainties, and risks described herein.

General information about IES Holdings, Inc. can be found at http://www.ies-co.com under “Investor Relations.” The Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, as well as any amendments to those reports, are available free of charge through the Company’s website as soon as reasonably practicable after they are filed with, or furnished to, the SEC.

         
IES HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(UNAUDITED)
         
    Three Months Ended   Year Ended
    September 30,   September 30,
      2026       2025       2026       2025  
Revenues $ 1,390.0     $ 897.8     $ 4,477.9     $ 3,371.5  
Cost of services   1,016.1       664.8       3,288.6       2,512.0  
  Gross profit   373.8       233.0       1,189.3       859.5  
Selling, general and administrative expenses   157.9       128.6       584.3       475.0  
Contingent consideration   —       0.1       0.4       1.1  
Gain on sale of assets   (1.2 )     —       (1.1 )     (0.2 )
  Operating income   217.2       104.3       605.7       383.5  
Interest and other income (expense):              
Interest expense   (0.4 )     (0.5 )     (3.4 )     (1.8 )
Gain (loss) on marketable securities   (3.8 )     3.7       76.6       8.3  
Other income, net   3.7       1.3       7.2       3.9  
  Income from operations before income taxes and equity method investment income   216.6       108.8       686.0       393.9  
Provision for income taxes   (58.1 )     (21.3 )     (176.1 )     (96.8 )
Equity method investment income   24.3       14.8       28.5       14.8  
  Net income   182.8       102.2       538.4       311.8  
Net income attributable to noncontrolling interest   (0.5 )     (0.4 )     (1.8 )     (5.8 )
  Net income attributable to IES Holdings, Inc. $ 182.3     $ 101.8     $ 536.6     $ 306.0  
                 
Computation of earnings per share:              
Net income attributable to IES Holdings, Inc. $ 182.3     $ 101.8     $ 536.6     $ 306.0  
Increase in noncontrolling interest   (0.5 )     (1.3 )     (1.1 )     (2.9 )
Net income attributable to common stockholders of IES Holdings, Inc. $ 181.8     $ 100.5     $ 535.5     $ 303.1  
                 
Earnings per share attributable to common stockholders(1):              
  Basic $ 4.56     $ 2.53     $ 13.44     $ 7.61  
  Diluted $ 4.50     $ 2.49     $ 13.24     $ 7.51  
                 
Shares used in the computation of earnings per share(1):              
  Basic (in thousands)   39,843       39,709       39,830       39,835  
  Diluted (in thousands)   40,448       40,308       40,442       40,366  

(1) Prior period results have been adjusted to reflect the two-for-one stock split effected in the form of a stock dividend in August 2026.

             
IES HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(DOLLARS IN MILLIONS)
(UNAUDITED)
             
        September 30,   September 30,
          2026       2025  
ASSETS      
  CURRENT ASSETS:      
    Cash and cash equivalents $ 155.1     $ 127.2  
    Marketable securities   288.9       104.6  
    Accounts receivable:      
      Trade, net of allowance   989.6       552.2  
      Retainage   169.6       99.9  
    Inventories   138.5       111.5  
    Costs and estimated earnings in excess of billings   163.1       69.2  
    Prepaid expenses and other current assets   41.5       20.9  
  Total current assets   1,946.4       1,085.5  
    Property and equipment, net   381.4       183.2  
    Goodwill   129.6       107.8  
    Intangible assets, net   50.0       41.6  
    Investments   88.2       59.7  
    Deferred tax assets   6.1       16.1  
    Operating right of use assets   108.9       88.4  
    Other non-current assets   11.4       13.3  
Total assets $ 2,721.9     $ 1,595.7  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
  CURRENT LIABILITIES:      
    Accounts payable and accrued expenses $ 714.2     $ 456.5  
    Billings in excess of costs and estimated earnings   492.8       176.8  
  Total current liabilities   1,207.0       633.4  
  Operating long-term lease liabilities   81.2       62.0  
  Other tax liabilities   4.0       6.8  
  Other non-current liabilities   14.5       5.5  
Total liabilities   1,306.6       707.7  
Noncontrolling interest   5.8       4.0  
  STOCKHOLDERS’ EQUITY:      
    Preferred stock   —       —  
    Common stock(1)   0.4       0.4  
    Treasury stock, at cost   (145.5 )     (127.8 )
    Additional paid-in capital(1)   218.1       210.4  
    Retained earnings   1,336.3       800.8  
Total stockholders’ equity   1,409.4       884.0  
Total liabilities and stockholders’ equity $ 2,721.9     $ 1,595.7  

(1) Prior period results have been adjusted to reflect the two-for-one stock split effected in the form of a stock dividend in August 2026.

     
IES HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(DOLLARS IN MILLIONS)
(UNAUDITED)
     
    Year Ended
      September 30,
      2026       2025  
CASH FLOWS FROM OPERATING ACTIVITIES:      
  Net income $ 538.4     $ 311.8  
  Adjustments to reconcile net income to net cash provided by operating activities:      
  Bad debt expense   3.4       3.4  
  Deferred financing cost amortization   0.6       0.5  
  Depreciation and amortization   63.3       46.9  
  Gain on sale of assets   (1.1 )     (0.2 )
  Non-cash compensation expense   15.0       12.9  
  Deferred income tax and other non-cash tax adjustments, net   13.7       (3.3 )
  Unrealized gain on marketable securities     (36.6 )     (7.5 )
  Gain on remeasurement of previously held investment upon acquisition   (2.8 )     —  
  Equity method investment income   (28.5 )     (14.8 )
  Changes in operating assets and liabilities:      
  Marketable securities   (151.7 )     (62.1 )
  Accounts receivable   (418.3 )     (79.9 )
  Inventories   (24.8 )     4.1  
  Costs and estimated earnings in excess of billings   (83.8 )     (8.7 )
  Prepaid expenses and other current assets   (85.1 )     (16.5 )
  Other non-current assets   (0.7 )     (1.6 )
  Accounts payable and accrued expenses   239.3       86.5  
  Billings in excess of costs and estimated earnings   315.0       16.1  
  Other non-current liabilities   9.3       (1.8 )
Net cash provided by operating activities   364.5       286.1  
CASH FLOWS FROM INVESTING ACTIVITIES:      
  Purchases of property and equipment   (163.1 )     (67.3 )
  Proceeds from sale of assets   2.9       0.8  
  Cash paid in conjunction with business combinations, net of cash acquired   (143.1 )     (44.9 )
  Purchases of equity investments   —       (52.4 )
Net cash used in investing activities   (303.3 )     (163.7 )
CASH FLOWS FROM FINANCING ACTIVITIES:      
  Borrowings of debt   190.0       996.4  
  Repayments of debt   (190.0 )     (996.4 )
  Cash paid for finance leases   (4.4 )     (4.4 )
  Purchase of noncontrolling interest   —       (40.0 )
  Settlement of contingent consideration liability   (2.5 )     (1.5 )
  Distribution to noncontrolling interest   (1.4 )     (8.6 )
  Purchase of treasury stock   (25.0 )     (41.6 )
Net cash used in financing activities   (33.3 )     (96.1 )
NET INCREASE IN CASH AND CASH EQUIVALENTS   27.9       26.3  
CASH and CASH EQUIVALENTS, beginning of period   127.2       100.8  
CASH and CASH EQUIVALENTS, end of period $ 155.1     $ 127.2  

         
IES HOLDINGS, INC. AND SUBSIDIARIES
OPERATING SEGMENT STATEMENT OF OPERATIONS
(DOLLARS IN MILLIONS)
(UNAUDITED)
    Three Months Ended   Year Ended
    September 30,   September 30,
      2026       2025       2026       2025  
Revenues              
  Communications $ 515.8     $ 335.4     $ 1,688.5     $ 1,140.6  
  Residential   320.3       320.5       1,216.1       1,304.5  
  Infrastructure Solutions   269.9       143.5       826.6       498.7  
  Commercial & Industrial   287.3       106.8       799.5       436.8  
  Corporate/Eliminations   (3.3 )     (8.4 )     (52.8 )     (9.1 )
Total revenue $ 1,390.0     $ 897.8     $ 4,477.9     $ 3,371.5  
                 
Operating income (loss)              
  Communications $ 87.8     $ 50.5     $ 290.0     $ 166.5  
  Residential   8.5       23.9       40.1       103.8  
  Infrastructure Solutions   63.5       36.1       194.4       118.5  
  Commercial & Industrial   77.7       11.5       163.1       47.3  
  Corporate/Eliminations   (20.3 )     (17.6 )     (81.9 )     (52.5 )
Total operating income $ 217.2     $ 104.3     $ 605.7     $ 383.5  

IES HOLDINGS, INC. AND SUBSIDIARIES
NON-GAAP RECONCILIATION OF ADJUSTED NET INCOME ATTRIBUTABLE
TO IES HOLDINGS, INC. AND ADJUSTED EARNINGS PER SHARE
ATTRIBUTABLE TO COMMON STOCKHOLDERS
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(UNAUDITED)

    Three Months Ended   Year Ended
    September 30,   September 30,
      2026       2025       2026       2025  
Net income attributable to IES Holdings, Inc. $  182.3         101.8      $  536.6      $  306.0   
(Gain) loss on marketable securities    3.8         (3.7 )      (76.6 )      (8.3 )
Equity method investment income (1)    (24.3 )      (14.8 )      (28.5 )      (14.8 )
Acquisition-related compensation expense (2)    1.4         —         6.4         —   
Provision for income taxes    58.1         21.3         176.1         96.8   
  Adjusted income from operations before income taxes    221.3         104.6         614.0         379.7   
Adjusted tax expense (3)    (56.2 )      (27.6 )      (154.2 )      (101.9 )
  Adjusted net income attributable to IES Holdings, Inc.    165.1         77.0         459.8         277.8   
                 
  Adjustments for computation of earnings per share:              
  Increase in noncontrolling interest    (0.5 )      (1.3 )      (1.1 )      (2.9 )
  Adjusted net income attributable to common stockholders $  164.6      $  75.7      $  458.7      $  274.9   
                 
Adjusted earnings per share attributable to common stockholders:              
  Basic $  4.13        1.91     $  11.52        6.90  
  Diluted $  4.07        1.88     $  11.34        6.81  
                 
Shares used in the computation of earnings per share:              
  Basic (in thousands)   39,843       39,709       39,830       39,835  
  Diluted (in thousands)   40,448       40,308       40,442       40,366  
                 
(1) Represents gains recorded by our equity investment, Jett Texas Company LLC, related to its investment in the CB&I storage solutions business.
(2) Represents expense associated with change in control awards and other stock-based compensation for former CEO and CFO of Gulf Island, to be paid out in cash upon completion of their employment agreements.
(3) Adjusted for the tax impact of adjustments to pretax income above.

       
IES HOLDINGS, INC. AND SUBSIDIARIES
NON-GAAP RECONCILIATION OF ADJUSTED EBITDA
(DOLLARS IN MILLIONS)
(UNAUDITED)
       
  Three Months Ended   Year Ended
    September 30,   September 30,
    2026       2025       2026       2025  
Net income attributable to IES Holdings, Inc. $ 182.3     $ 101.8     $ 536.6     $ 306.0  
Equity method investment income   (24.3 )     (14.8 )     (28.5 )     (14.8 )
Provision for income taxes   58.1       21.3       176.1       96.8  
Interest expense   0.4       0.5       3.4       1.8  
(Gain) loss on marketable securities   3.8       (3.7 )     (76.6 )     (8.3 )
Other income, net   (3.7 )     (1.3 )     (7.2 )     (3.8 )
Depreciation and amortization   17.6       12.2       63.3       46.9  
EBITDA $ 234.3     $ 116.0     $ 667.1     $ 424.6  
Non-cash equity compensation expense   3.9       3.5       15.0       12.9  
Acquisition-related compensation expense(1)   1.4       —       6.4       —  
Adjusted EBITDA $ 239.5     $ 119.5     $ 688.5     $ 437.5  
(1)Represents expense associated with change in control awards and other stock-based compensation for former CEO and CFO of Gulf Island, to be paid out in cash upon completion of their employment agreements.

           
IES HOLDINGS, INC. AND SUBSIDIARIES
SUPPLEMENTAL REMAINING PERFORMANCE OBLIGATIONS AND NON-GAAP RECONCILIATION OF BACKLOG DATA
(DOLLARS IN MILLIONS)
(UNAUDITED)
           
  September 30, 2026   June 30, 2026   September 30, 2025
  Remaining Performance Obligations Agreements without an enforceable obligation(1) Backlog   Remaining Performance Obligations Agreements without an enforceable obligation(1) Backlog   Remaining Performance Obligations Agreements without an enforceable obligation(1) Backlog
  (Dollars in millions)
Communications $ 2,003.3 $ 150.6 $ 2,153.9   $ 1,329.3 $ 282.8 $ 1,612.1   $ 692.2 $ 63.6 $ 755.8
Residential   297.0   79.1   376.1     278.3   103.5   381.8     252.0   121.5   373.6
Infrastructure Solutions(2)   310.5   885.1   1,195.6     355.5   773.7   1,129.2     128.7   490.5   619.2
Commercial & Industrial   872.1   360.1   1,232.3     838.5   563.5   1,402.0     613.6   11.5   625.2
Total $ 3,482.9 $ 1,474.9 $ 4,957.9   $ 2,801.6 $ 1,723.5 $ 4,525.1   $ 1,686.5 $ 687.1 $ 2,373.8
                       
(1)Our backlog contains signed agreements and letters of intent which we do not have a legal right to enforce prior to work starting. These arrangements are excluded from remaining performance obligations until work begins.
(2)In January 2026, Infrastructure Solutions acquired $29.1 million of remaining performance obligations and backlog in connection with the acquisition of Gulf Island.

Transaction remains subject to Nasdaq approval and other closing conditions

SOUTHLAKE, Texas, Nov. 20, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its shareholders approved the proposed business combination (the “Proposed Transaction”) with Fortitude Mining Holdings, Inc. (“Fortitude”) at the Company’s special meeting of shareholders held today.

Detailed voting results for the proposals considered at the special meeting will be reported in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

“We appreciate the participation and support of our shareholders,” said Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences. “Today’s vote is an important step toward completing our proposed business combination with Fortitude. We are working with Fortitude to satisfy the remaining closing conditions and will provide an update when the transaction closes.”

Upon completion of the Proposed Transaction, the combined company is expected to operate as Fortitude Mining Group, Inc., and its Class A common stock is expected to trade on Nasdaq under the symbol “TUDE,” subject to Nasdaq approval. Completion of the transaction remains subject to the applicable listing requirements and other closing conditions under the merger agreement.

About Fortitude

Fortitude is establishing a new category of public infrastructure as a premier vertically-integrated Zcash mining platform. Following the expected closing of its business combination with HeartSciences, Fortitude is preparing to commence trading on the Nasdaq under the ticker TUDE. Like Bitcoin, Zcash relies on secure proof of work mining, but it is designed to power the privacy economy by validating transactions without exposing underlying financial data. Upon its market debut, Fortitude believes it will offer investors a regulated vehicle for direct exposure to this growing ecosystem. Driven by a seasoned management team, Fortitude pairs self-mining operations with an owned data center footprint and a controlled power portfolio to scale high conviction opportunities across the broader digital asset landscape.

For more information, visit Fortitude Mining and follow Fortitude on X at @FortitudeCrypto

In the ordinary course of business, Fortitude currently sells or otherwise monetizes all the digital assets that it mines, including ZEC. In addition, Fortitude and its affiliates and subsidiaries, including DCG, from time to time sell, pledge or otherwise monetize their digital asset holdings, including ZEC. The funds received from such sales, pledges, or other monetization activities are used to fund operating expenses and capital investments, as well as for other purposes, including to hedge exposures and realize investment gains.

About HeartSciences Inc.

HeartSciences is a healthcare information technology company advancing the use of electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ platform is a device-agnostic ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting AI-enabled solutions.

For more information, visit www.heartsciences.com

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally can be identified by the use of words such as “aim,” “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “potential,” “target,” “objective,” “intend,” and other words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, express or implied statements relating to timing and contents of future HeartSciences’ SEC filings and HeartSciences’ management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding the anticipated closing of the Proposed Transaction and its expected effects, perceived benefits or opportunities, including related to value creation, and the listing as “TUDE” on Nasdaq. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of the HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release are discussed in HeartSciences’ filings with the SEC, including its most recent Annual Report on Form 10-K, filed with the SEC on July 23, 2026, Quarterly Reports on Form 10-Q, and other reports filed with the SEC from time to time, and are discussed in the definitive proxy statement filed by HeartSciences with the SEC in connection with the Proposed Transaction. Readers are cautioned not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. All forward-looking statements are made as of the date of this press release.

Investor Relations Contact
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us
Email: investorrelations@heartsciences.com

HOTEL101-JOHOR BAHRU WITH APPROX. 606 ROOMS IS EXPECTED TO BE THE LARGEST HOTEL BY ROOM COUNT IN JOHOR BAHRU, MALAYSIA

LOCATED AT A PRIME SITE AROUND 2 MINUTES DRIVE TO THE JOHOR BAHRU-SINGAPORE RTS TRAIN LINK

Today, November 20, 2026: Hotel101 Global signs definitive binding agreements for the development of Hotel101-Johor Bahru, Malaysia

Hotel101-Johor Bahru is set to have approx. 606 rooms on a 3,535 sqm site located on the corner of Jalan Tun Abdul Razak and the Johor Bahru Inner Ring Road, only around 2 minutes from the Bukit Chagar RTS Link Station, the key hub of the Johor Bahru-Singapore RTS Link

Hotel101-Johor Bahru is expected to generate MYR275.73 million (US$66.78 million) in sales revenues

Johor Bahru is reported to have seen roughly 430,000-450,000 daily cross-border travellers, or more than 140 million a year, creating a constant stream of short-stay guests in Johor Bahru

Some of the branded hotels currently operating in Johor Bahru include the Sheraton, Hyatt, Holiday Inn, Novotel, and DoubleTree by Hilton.

(Satellite Location Map of the Hotel101-Johor Bahru location)
(Satellite Location Map of the Hotel101-Johor Bahru location)
(Satellite Location Map of the Hotel101-Johor Bahru location)

Hotel101-Johor Bahru site
In photo at the Hotel101-Johor Bahru site set to become the largest hotel in room count in the whole of Johor Bahru Malaysia is Hotel101 Global Founder Edgar Injap Sia II with Hotel101 Global CEO Hannah Yulo-Luccini and Hotel101 Global Chief Development Officer Catherine Chan
In photo at the Hotel101-Johor Bahru site set to become the largest hotel in room count in the whole of Johor Bahru Malaysia is Hotel101 Global Founder Edgar Injap Sia II with Hotel101 Global CEO Hannah Yulo-Luccini and Hotel101 Global Chief Development Officer Catherine Chan

SINGAPORE, Nov. 20, 2026 (GLOBE NEWSWIRE) — Hotel101 Global Holdings Corp. (NASDAQ Ticker: HBNB) (“Hotel101” or “Hotel101 Global”), a leading asset-light, prop-tech hospitality platform pioneering a globally standardized “condotel” business model, listed on the Nasdaq Stock Exchange and a subsidiary of Philippine-listed DoubleDragon Corporation (PSE Ticker: DD), announces the signing of definitive binding agreements for the development of an approx. 606-room Hotel101-Johor Bahru, Malaysia.

Hotel101 Global Team believes it ensures all its projects via direct developments, joint ventures and licensing to local developers in various countries worldwide are in prime and strategic locations.

The project situated at the Flagship A of Johor-Singapore Special Economic Zone (JS-SEZ). JS-SEZ is a cross-border economic partnership between Malaysia and Singapore, established via bilateral agreement in January 2025, that pairs Johor’s land, resources, and cost-competitive manufacturing capacity with Singapore’s capital, financial services, and global connectivity. Spanning roughly 3,500 square kilometers across southern Johor with flagship zones and promoted sectors ranging from digital economy, manufacturing, and logistics to green energy and services, the zone offers tailored incentives, streamlined approvals, and improved cross-border movement to attract high-value investment and create skilled jobs.

The hotel, to be named Hotel101-Johor Bahru, is planned to occupy a prime site on the corner of Jalan Tun Abdul Razak and the Johor Bahru Inner Ring Road in the heart of Johor Bahru’s central business district. This strategic position is expected to offer guests excellent connectivity, sitting only around two minutes from the Bukit Chagar RTS Link Station—the key Malaysian hub of the Johor Bahru-Singapore RTS Link that is expected to connect directly to Woodlands North in Singapore in around five minutes. The area has rapidly emerged as one of Johor’s key growth districts, known for its modern infrastructure, improving transport links, and strong mix of residential, commercial, and tourism developments, while sitting at the centre of one of the world’s busiest land border crossings.

Key Location Advantages:

  • Prime Jalan Tun Abdul Razak Position: Located at the corner of Jalan Tun Abdul Razak and the Johor Bahru Inner Ring Road with direct access to the city’s main arterial routes. Upon completion, guests are expected to benefit from outstanding road connectivity and proximity to the upcoming RTS Link.
  • Proximity to Major Attractions and Connectivity: Situated within the Johor Bahru CBD that is expected to be served by the upcoming RTS Link, JB Sentral, major shopping malls, and the wider cross-border market. The site is expected to offer a balance of modern urban development and strong cross-border demand, with easy access to key commercial amenities, residential communities, and the reported 430,000–450,000 daily travellers moving between Malaysia and Singapore.

When completed, Hotel101-Johor Bahru is expected to generate approx. MYR275.73 million (US$66.78 million) in sales revenue once fully sold and is expected to be the largest hotel by room count in Johor Bahru, Malaysia, forming part of Hotel101 Global’s global expansion strategy.

Hotel101-Johor Bahru is expected to offer 4-star amenities at affordable prices, including a ballroom, ample meeting spaces, and a conference center tailored for business events. Consistent with Hotel101’s offerings across its locations globally, guests are expected to enjoy modern rooms, 24/7 reception, all-day dining, swimming pools, a full-size gym, a business center, children’s playground, ample parking, luggage storage, and other amenities.

The development is subject to customary governmental, regulatory, corporate and other approvals.

About Hotel101 Global

Listed on Nasdaq (Ticker: HBNB) with a market capitalization of approx. US$1 billion as of November 18, 2026, Hotel101 is an asset-light, prop-tech hospitality platform pioneering a globally standardized “condotel” business model. Hotel101 aims to disrupt the global hotel and hospitality sector through its unique tech-enabled business model that positions it to generate revenues twice: first from the advance sale of individual hotel units during the construction phase; and second, from long-term recurring revenue derived from day-to-day hotel operations. The expansion of Hotel101 toward its long-term goal to operate in 100 countries globally is expected to be driven mainly by joint ventures and, in the future, license agreements with local developers in various countries worldwide.

The Hotel101 Global Group is advancing its global expansion plans toward its medium-term goal to be in 25 countries and its long-term goal of operating one million Hotel101 rooms in 100 countries globally.

(Aerial views of the Hotel101-Johor Bahru location)
(Aerial views of the Hotel101-Johor Bahru location)
(Aerial views of the Hotel101-Johor Bahru location)

(Aerial views of the Hotel101-Johor Bahru location)
(Aerial views of the Hotel101-Johor Bahru location)
(Aerial views of the Hotel101-Johor Bahru location)

Hotel101 Johor Bahru

Forward-Looking Statements

This document includes certain “forward-looking statements” within the meaning of securities laws of certain jurisdictions, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this document, including statements regarding the future financial position, business strategy, plans and objectives of management for future operations of Hotel101 Global Holdings Corp. (“HBNB”) and its subsidiaries (the “HBNB Group”), are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “set,” “expect,” “predict,” “potential” or the negative of these terms or other similar expressions. Forward-looking statements include, without limitation, HBNB’s expectations concerning anticipated sales revenue once fully sold and project value, the project location, expected number of rooms, expected project completion date and expansion goals, the outlook for the HBNB Group’s business, productivity, plans and goals for future operational improvements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, as well as any information concerning possible or assumed future results of operations of the HBNB Group. These forward-looking statements are based on the beliefs and assumptions of the management of HBNB. Although HBNB believes that such plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, HBNB cannot assure you that such plans, intentions or expectations will be achieved or realized. Forward-looking statements involve a number of risks, uncertainties and assumptions and actual results or events may differ materially from those projected or implied in those statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the HBNB Group’s ability to execute on its business model, potential business expansion opportunities in foreign countries and growth strategies, manage future growth, retain and expand customers’ use of its hotel services and attract new customers, and source and maintain talent; risks relating to joint venture partners, including owners of pre-sold condotel units in Hotel101 hospitality projects, who may have interests different from and may take actions that adversely affect the HBNB Group; risks relating to project cost and completion; risks relating to the HBNB Group’s sources of cash and cash resources; risks relating to offering deferred payment schemes, including the risk of customer default; the HBNB Group’s ability to effectively compete in the highly competitive hospitality industry; any declines or disruptions in the travel and hospitality industries or economic downturn; applicable laws and regulations to real estate development and marketing activities and hotel operation and management activities in the jurisdictions where the HBNB Group has operations or intends to expand into; and other risks and uncertainties discussed in HBNB’s annual report for the year ended December 31, 2025 on Form 20-F and under the heading “Risk Factors” in HBNB’s registration statement on Form F-4 (File No.: 333-287130) and other documents to be filed by HBNB from time to time with the U.S. Securities and Exchange Commission.

The foregoing list of factors is not exhaustive. Should one or more of these risks or uncertainties materialize, or should any of HBNB’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that are not presently known to HBNB or that HBNB currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. HBNB cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date hereof. Forward-looking statements set forth herein speak only as of the date of this document. HBNB does not undertake any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that HBNB will make additional updates with respect to that statement, related matters or any other forward-looking statements.

Contact information:
ir@hotel101global.com

Photos accompanying this announcement are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/3a01c237-58b2-4514-9541-b294f8950710
https://www.globenewswire.com/NewsRoom/AttachmentNg/306ab2d4-a27d-4ee4-b887-158fc70cf434
https://www.globenewswire.com/NewsRoom/AttachmentNg/f019e2a4-a2c3-4ef7-98a4-5d584b96b24a
https://www.globenewswire.com/NewsRoom/AttachmentNg/8fe9a76a-ab17-4aaa-a00e-6c48f4bfea2f
https://www.globenewswire.com/NewsRoom/AttachmentNg/1c8909df-506d-497d-9172-1256b0b57a81

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.